BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riello L, Talbotec C, Garnier-Lengliné H, Pigneur B, Svahn J, Canioni D, Goulet O, Schmitz J, Ruemmele FM. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138-2143. [PMID: 21910176 DOI: 10.1002/ibd.21612] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Hammer MR, Podberesky DJ, Dillman JR. Multidetector Computed Tomographic and Magnetic Resonance Enterography in Children. Radiologic Clinics of North America 2013;51:615-36. [DOI: 10.1016/j.rcl.2013.04.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
2 Hojsak I, Pavić AM, Mišak Z, Kolaček S. Risk factors for relapse and surgery rate in children with Crohn's disease. Eur J Pediatr 2014;173:617-21. [PMID: 24310524 DOI: 10.1007/s00431-013-2230-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
3 Nguyen TV, Nguyen TM, Lachaux A, Boulieu R. Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients. J Clin Pharmacol 2013;53:900-8. [PMID: 23856979 DOI: 10.1002/jcph.134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. The Lancet Child & Adolescent Health 2017;1:147-58. [DOI: 10.1016/s2352-4642(17)30017-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
5 Scherkenbach LA, Stumpf JL. Methotrexate for the Management of Crohn's Disease in Children. Ann Pharmacother 2016;50:60-9. [PMID: 26511908 DOI: 10.1177/1060028015613527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
6 Konidari A, Anagnostopoulos A, Bonnett LJ, Pirmohamed M, El-Matary W. Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol 2014;78:467-76. [PMID: 24592889 DOI: 10.1111/bcp.12365] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
7 Duncan H, Buchanan E, Cardigan T, Garrick V, Curtis L, McGrogan P, Barclay A, Russell RK. A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing! BMC Gastroenterol. 2014;14:50. [PMID: 24645851 DOI: 10.1186/1471-230x-14-50] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
8 Boyle BM, Kappelman MD, Colletti RB, Baldassano RN, Milov DE, Crandall WV. Routine use of thiopurines in maintaining remission in pediatric Crohn’s disease. World J Gastroenterol 2014; 20(27): 9185-9190 [PMID: 25083093 DOI: 10.3748/wjg.v20.i27.9185] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
9 Chaparro M, Garre A, Ricart E, Iglesias-Flores E, Taxonera C, Domènech E, Gisbert JP; ENEIDA study group. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther 2019;49:419-28. [PMID: 30637837 DOI: 10.1111/apt.15114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
10 van Hoeve K, Hoffman I, D'Hoore A, Ferrante M, Vermeire S. Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease. Dig Liver Dis 2020;52:164-72. [PMID: 31640916 DOI: 10.1016/j.dld.2019.09.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ong C, Lim PT, Logarajah V, Liwanag MJ, Ang BX, Cher Y, Chiou FK, Kader A. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease. BMC Gastroenterol 2018;18:185. [PMID: 30541458 DOI: 10.1186/s12876-018-0907-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Djurić Z, Šaranac L, Budić I, Pavlović V, Djordjević J. Therapeutic role of methotrexate in pediatric Crohn's disease. Bosn J Basic Med Sci 2018;18:211-6. [PMID: 29338679 DOI: 10.17305/bjbms.2018.2792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Nguyen TV, Vu DH, Nguyen TM, Lachaux A, Boulieu R. Exploring associations of 6-thioguanine nucleotide levels and other predictive factors with therapeutic response to azathioprine in pediatric patients with IBD using multilevel analysis. Inflamm Bowel Dis 2013;19:2404-10. [PMID: 24013359 DOI: 10.1097/MIB.0b013e3182a508c6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
14 Li T, Qiu Y, Li X, Zhuang X, Huang S, Li M, Feng R, Chen B, He Y, Zeng Z, Chen M, Zhang S. Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients. Front Med (Lausanne) 2020;7:557986. [PMID: 33240902 DOI: 10.3389/fmed.2020.557986] [Reference Citation Analysis]
15 Wintzell V, Svanström H, Olén O, Melbye M, Ludvigsson JF, Pasternak B. Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study. Lancet Child Adolesc Health 2019;3:158-65. [PMID: 30685366 DOI: 10.1016/S2352-4642(18)30401-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
16 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
17 Lund JL, Cook SF, Allen JK, Carroll CF, Kappelman MD. Patterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn’s disease in the United States. Clin Epidemiol. 2013;5:501-512. [PMID: 24348071 DOI: 10.2147/clep.s51625] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Aloi M, Nuti F, Stronati L, Cucchiara S. Advances in the medical management of paediatric IBD. Nat Rev Gastroenterol Hepatol. 2014;11:99-108. [PMID: 23958601 DOI: 10.1038/nrgastro.2013.158] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
19 Grover Z, Lewindon P. Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated Early with Thiopurines. Dig Dis Sci 2015;60:3069-74. [PMID: 26038093 DOI: 10.1007/s10620-015-3722-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
20 Frivolt K, Schwerd T, Werkstetter KJ, Schwarzer A, Schatz SB, Bufler P, Koletzko S. Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome. Aliment Pharmacol Ther. 2014;39:1398-1407. [PMID: 24779671 DOI: 10.1111/apt.12770] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
21 Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A. Use of thiopurines in inflammatory bowel disease: an update. Intest Res 2022;20:11-30. [PMID: 33845546 DOI: 10.5217/ir.2020.00155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
22 Atia O, Ledder O, Ben-moshe T, Lev-tzion R, Rachmen Y, Meyer EO, Beeri R, Renbaum P, Shamasneh I, Shteyer E, Turner D. Role of Thiopurines in Pediatric Inflammatory Bowel Diseases: A Real-Life Prospective Cohort Study. Journal of Pediatric Gastroenterology & Nutrition 2020;70:825-32. [DOI: 10.1097/mpg.0000000000002566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
23 de’Angelis N, Carra MC, Borrelli O, Bizzarri B, Vincenzi F, Fornaroli F, De Caro G, de’Angelis GL. Short- and long-term efficacy of endoscopic balloon dilation in Crohn’s disease strictures. World J Gastroenterol 2013; 19(17): 2660-2667 [PMID: 23674873 DOI: 10.3748/wjg.v19.i17.2660] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
24 Agrawal G, Clancy A, Sharma R, Huynh R, Ramrakha S, Borody T. Targeted Combination Antibiotic Therapy Induces Remission in Treatment-Naïve Crohn's Disease: A Case Series. Microorganisms 2020;8:E371. [PMID: 32155771 DOI: 10.3390/microorganisms8030371] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
25 van Hoeve K, Vermeire S. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place. Paediatr Drugs 2020;22:449-61. [PMID: 32797366 DOI: 10.1007/s40272-020-00411-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: Safety issues. World J Gastrointest Pharmacol Ther 2014; 5(2): 63-76 [PMID: 24868487 DOI: 10.4292/wjgpt.v5.i2.63] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
27 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 580] [Cited by in F6Publishing: 470] [Article Influence: 72.5] [Reference Citation Analysis]
28 Harris RE, Hegde V, Curtis L, Garrick V, Gervais L, Armstrong L, Delahunty C, Eccleston A, Al-Hourani G, Flynn DM, Merrick V, Barclay AR, Tayler R, Hansen R, Russell RK. Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population. J Pediatr Gastroenterol Nutr 2021;73:358-62. [PMID: 34091548 DOI: 10.1097/MPG.0000000000003197] [Reference Citation Analysis]
29 Jagt JZ, Pothof CD, Buiter HJC, van Limbergen JE, van Wijk MP, Benninga MA, de Boer NKH, de Meij TGJ. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study. Dig Dis Sci 2021. [PMID: 33532972 DOI: 10.1007/s10620-021-06836-3] [Reference Citation Analysis]
30 Hradsky O, Copova I, Zarubova K, Nevoral J, Bronsky J. Time to Relapse in Children with Crohn's Disease Treated with Azathioprine and Nutritional Therapy or Corticosteroids. Dig Dis Sci 2016;61:2041-50. [PMID: 26971092 DOI: 10.1007/s10620-016-4103-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Malgras B, Pautrat K, Dray X, Pasquier P, Valleur P, Pocard M, Soyer P. Multidisciplinary Management of Gastrointestinal Fibrotic Stenosis in Crohn’s Disease. Dig Dis Sci 2015;60:1152-68. [DOI: 10.1007/s10620-014-3421-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
32 Sunseri W, Hyams JS, Lerer T, Mack DR, Griffiths AM, Otley AR, Rosh JR, Carvalho R, Grossman AB, Cabrera J, Pfefferkorn MD, Rick J, Leleiko NS, Hitch MC, Oliva-hemker M, Saeed SA, Kappelman M, Markowitz J, Keljo DJ. Retrospective Cohort Study of Methotrexate Use in the Treatment of Pediatric Crohnʼs Disease: . Inflammatory Bowel Diseases 2014;20:1341-5. [DOI: 10.1097/mib.0000000000000102] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 3.1] [Reference Citation Analysis]
33 de Bie C, Kindermann A, Escher J. Use of exclusive enteral nutrition in paediatric Crohn’s disease in The Netherlands. J Crohns Colitis. 2013;7:263-270. [PMID: 22820027 DOI: 10.1016/j.crohns.2012.07.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
34 Lev-Tzion R, Renbaum P, Beeri R, Ledder O, Mevorach R, Karban A, Koifman E, Efrati E, Muise AM, Chowers Y, Turner D. Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2015;61:404-7. [PMID: 25885881 DOI: 10.1097/MPG.0000000000000820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]